Pyrido-pyrimidines — with analgesic and anti-inflammatory activity — inhibit the gastrointestinal mucosal damage induced by different prostaglandin synthesis inhibitors

Abstract

The pyrido-pyrimidines (PPs), possess analgesic and anti-inflammatory activity^1,2. Combining them with indomethacin or suprofen their anti-inflammatory and analgesic activity were enhanced². On the other hand PPs inhibit the gastric damage induced by indomethacin, suprofen, acetylsalicylic acid, naproxen or zomepirac following both oral and subcutaneous administration. PPs inhibited the intestinal lesions induced by indomethacin as we11³, in contrast to atropine (1 mg/kg) or cimetidine (25 mg/kg), which were effective only against the gastric lesions but not against the intestinal mucosal damage induced by indomethacin. One of the most potent pyrido-pyrimidine derivatives was rimazolium (1,6-dimethyl-3-carbetoxy-4-oxo-6,7,8,9 tetrahydrohomopyrimidazole), which has been marketed in Hungary since 1975.

This a summary of a poster presentation